Global Cord Blood (CORBF) Competitors $1.35 +0.64 (+90.14%) As of 08/5/2025 02:11 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock CORBF vs. FTRE, FLGT, LFMD, PSNL, INNV, AUNA, OMDA, SBC, CSTL, and TALKShould you be buying Global Cord Blood stock or one of its competitors? The main competitors of Global Cord Blood include Fortrea (FTRE), Fulgent Genetics (FLGT), LifeMD (LFMD), Personalis (PSNL), InnovAge (INNV), Auna (AUNA), Omada Health (OMDA), SBC Medical Group (SBC), Castle Biosciences (CSTL), and Talkspace (TALK). These companies are all part of the "healthcare" industry. Global Cord Blood vs. Its Competitors Fortrea Fulgent Genetics LifeMD Personalis InnovAge Auna Omada Health SBC Medical Group Castle Biosciences Talkspace Fortrea (NASDAQ:FTRE) and Global Cord Blood (NYSE:CORBF) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations. Which has higher valuation and earnings, FTRE or CORBF? Global Cord Blood has lower revenue, but higher earnings than Fortrea. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFortrea$2.69B0.22-$328.50M-$8.79-0.75Global Cord Blood$196.12M0.84$79.04MN/AN/A Is FTRE or CORBF more profitable? Global Cord Blood has a net margin of 0.00% compared to Fortrea's net margin of -29.43%. Fortrea's return on equity of 2.84% beat Global Cord Blood's return on equity.Company Net Margins Return on Equity Return on Assets Fortrea-29.43% 2.84% 1.06% Global Cord Blood N/A N/A N/A Does the media prefer FTRE or CORBF? In the previous week, Fortrea had 38 more articles in the media than Global Cord Blood. MarketBeat recorded 38 mentions for Fortrea and 0 mentions for Global Cord Blood. Fortrea's average media sentiment score of 0.44 beat Global Cord Blood's score of 0.00 indicating that Fortrea is being referred to more favorably in the media. Company Overall Sentiment Fortrea Neutral Global Cord Blood Neutral Do analysts recommend FTRE or CORBF? Fortrea currently has a consensus price target of $13.73, suggesting a potential upside of 108.62%. Given Fortrea's stronger consensus rating and higher possible upside, equities research analysts plainly believe Fortrea is more favorable than Global Cord Blood.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fortrea 2 Sell rating(s) 10 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.07Global Cord Blood 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, FTRE or CORBF? Fortrea has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Comparatively, Global Cord Blood has a beta of -0.52, meaning that its stock price is 152% less volatile than the S&P 500. SummaryFortrea beats Global Cord Blood on 10 of the 13 factors compared between the two stocks. Get Global Cord Blood News Delivered to You Automatically Sign up to receive the latest news and ratings for CORBF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CORBF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CORBF vs. The Competition Export to ExcelMetricGlobal Cord Bloodhealth & allied services, not elsewhere classified IndustryMedical SectorNYSE ExchangeMarket Cap$164.09M$90.74M$5.57B$20.65BDividend YieldN/AN/A4.31%3.66%P/E RatioN/A0.5529.3729.27Price / Sales0.840.51444.1862.32Price / Cash1.402.8035.8423.31Price / BookN/A0.118.084.37Net Income$79.04M$43.11M$3.26B$996.36M7 Day Performance90.14%30.05%0.45%0.59%1 Month Performance145.45%32.52%4.83%0.23%1 Year Performance-10.00%31.40%30.28%16.71% Global Cord Blood Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CORBFGlobal Cord BloodN/A$1.35+90.1%N/A-10.0%$164.09M$196.12M0.001,200Gap UpFTREFortrea4.2204 of 5 stars$6.56+2.2%$13.73+109.3%-74.9%$581.01M$2.70B-0.7515,500Trending NewsEarnings ReportAnalyst UpgradeGap UpTrading HaltedFLGTFulgent Genetics3.783 of 5 stars$20.78+13.2%$25.33+21.9%-14.9%$561.98M$283.47M-12.521,313Earnings ReportAnalyst ForecastHigh Trading VolumeLFMDLifeMD2.3469 of 5 stars$11.84-4.1%$13.86+17.0%+12.9%$561.28M$212.45M-34.82230Trending NewsAnalyst ForecastGap DownHigh Trading VolumePSNLPersonalis3.7221 of 5 stars$5.64+1.3%$7.67+35.9%+37.8%$491.97M$84.61M-4.37400Trending NewsEarnings ReportAnalyst ForecastGap DownINNVInnovAge1.426 of 5 stars$3.45-3.9%$5.00+44.9%-42.0%$484.70M$763.85M-15.002,350AUNAAuna3.5882 of 5 stars$6.30+0.8%$10.70+69.8%-18.5%$462.58M$1.17B10.8614,842OMDAOmada HealthN/A$17.33-2.9%$23.86+37.7%N/A$459.38MN/A0.00849Positive NewsSBCSBC Medical GroupN/A$4.37+1.2%N/AN/A$447.60M$205.42M0.00N/ACSTLCastle Biosciences3.2187 of 5 stars$20.35+32.8%$37.00+81.8%-20.6%$442.32M$332.07M-58.14540Earnings ReportHigh Trading VolumeTALKTalkspace3.808 of 5 stars$2.27-3.8%$4.50+98.2%+38.5%$394.86M$187.59M113.56500Trending NewsEarnings ReportAnalyst RevisionHigh Trading Volume Related Companies and Tools Related Companies FTRE Competitors FLGT Competitors LFMD Competitors PSNL Competitors INNV Competitors AUNA Competitors OMDA Competitors SBC Competitors CSTL Competitors TALK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CORBF) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Global Cord Blood Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Global Cord Blood With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
